Putcha L, Cintrón N M
Biomedical Operations and Research Branch, NASA-Johnson Space Center, Houston, Texas 77058.
Ann N Y Acad Sci. 1991 Feb 28;618:615-8. doi: 10.1111/j.1749-6632.1991.tb27292.x.
Spaceflight induces a wide range of physiological and biochemical changes, including disruption of gastrointestinal (GI) function, fluid and electrolyte balance, circulatory dynamics, and organ blood flow, as well as hormonal and metabolic perturbations. Any of these changes can influence the pharmacokinetics and pharmacodynamics of in-flight medication. That spaceflight may alter bioavailability was proposed when drugs prescribed to alleviate space motion sickness (SMS) had little therapeutic effect. Characterization of the pharmacokinetic and/or pharmacodynamic behavior of operationally critical medications is crucial for their effective use in flight; as a first step, we sought to determine whether drugs administered in space actually reach the site of action at concentrations sufficient to elicit the therapeutic response.
太空飞行会引发广泛的生理和生化变化，包括胃肠（GI）功能紊乱、体液和电解质平衡失调、循环动力学改变以及器官血流变化，还有激素和代谢紊乱。这些变化中的任何一种都可能影响飞行中药物的药代动力学和药效学。当用于缓解太空晕动病（SMS）的药物疗效甚微时，有人提出太空飞行可能会改变生物利用度。了解关键操作药物的药代动力学和/或药效学行为对于其在飞行中的有效使用至关重要；作为第一步，我们试图确定在太空中给药的药物是否真的能以足以引发治疗反应的浓度到达作用部位。
